Helicos Promotes Steve Lombardi to President

Helicos BioSciences Corporation

Helicos Promotes Steve Lombardi to President

October 3, 2007

Stan Lapidus Appointed Chairman of the Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (Nasdaq:HLCS) announced today that it has promoted Stephen J. Lombardi to President and Chief Operating Officer of the company, reporting to Stanley N. Lapidus, co-founder and Chief Executive Officer. Mr. Lombardi previously served as Chief Operating Officer and Executive Vice President. In addition, the company announced that Mr. Lapidus has been named as Chairman of the Board of Directors and that Noubar B. Afeyan, co-founder and previous Chairman of the Board of Directors, has been appointed as Lead Independent Director of the Board.

"Since joining the company, Steve has established a record of success in building a seasoned executive team and commercial infrastructure to support the launch of the world's first single molecule genetic analyzer,” said Mr. Lapidus. “We are delighted to have Steve in his new role at this important stage of our growth.”

"I am very energized about this new opportunity," stated Mr. Lombardi. "I am proud to be part of the Helicos team and am optimistic about our ability to bring the scientific and business promise of True Single Molecule Sequencing to our customers.”

Prior to joining Helicos, Mr. Lombardi served as a Senior Vice President at Affymetrix between 2002 and 2006. Previously, he worked for 16 years at Applied Biosystems (AB), a division of Applera Corporation. At Applied Biosystems, Lombardi worked in various business and executive roles, most notably the leader of its DNA sequencing and genetic analysis business from 1989 to 1998.

About Helicos BioSciences

Helicos BioSciences Corporation is a life sciences company developing innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The company has developed its proprietary True Single Molecule Sequencing (tSMS) technology to enable ultra-high-throughput genetic analysis based on the direct sequencing of single molecules of nucleic acids. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, Helicos' expectations concerning the prospective value of Steve Lombardi’s experiences and expertise to Helicos and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Helicos' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully complete the manufacturing process and commercialize the HeliScope system; competition; changing technology and customer requirements; our ability to operate in an emerging market; market acceptance of our technology; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our rapid growth and our ability to obtain capital when desired on favorable terms. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos' public filings with the Securities and Exchange Commission.


Financial Contact:
Helicos BioSciences Corporation
Louise Mawhinney, 617-264-1800
Sr. Vice President and Chief Financial Officer


Media Contact:
Racepoint Group
Sally Bain, 781-487-4647